Prescient Therapeutics PTX-100 shows promising results in Phase 1b study

Spread the love

–News Direct–

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the results of its PTX-100 Phase 1b study at the 15th Annual T-Cell Lymphoma Forum (TCLF) in California from June 6 to 8. The Phase 1b study targeted patients with relapsed and refractory T-cell lymphomas (r/r TCLs) and successfully met its primary objectives of demonstrating safety and determining pharmacokinetics and pharmacodynamics. Additionally, the study showed a promising preliminary efficacy with a 45% overall response rate, where five out of 11 evaluable patients responded positively to the treatment. T-cell lymphomas are a rare type of non-Hodgkin lymphoma, classified as an orphan disease with about 30,000 cases. PTX-100 has received Orphan Drug Designation from the US FDA, highlighting the need for more effective treatments for TCLs, particularly for relapsed and refractory cases. The T-Cell Lymphoma Forum is a specialised conference focused on advancements in TCL treatment, bringing together clinicians, scientists and industry professionals. Yatomi-Clarke, emphasised the importance of this platform for sharing critical research and the significance of PTX-100 in addressing an unmet medical need. The company plans to advance to a Phase 2 trial in r/r TCL, expected to commence in Q3 2024.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

[email protected]

View source version on


comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No State Today USA journalist was involved in the writing and production of this article.

Written by